Figure 7.

Loss of RAF kinase inhibitor protein (RKIP) is a frequent event in primary chronic myelomonocytic leukemia (CMML) patients’ samples. (A) Loss of RKIP at protein level was observed in 12 of 41 (29.3%) of cases. A representative immunoblot is shown, with RKIP protein loss being present in patients 8039, 7156 and 7954. (B) Graphs showing the x-fold change in RKIP protein expression as compared with NB4 acute myeloid leukemia (AML) cells, which were chosen as a calibrator due to their physiological RKIP expression levels.¹² The expression of NB4 was arbitrarily set to 1. (C) Box plots illustrating RKIP mRNA levels in CMML patients with and without RKIP loss at the protein level. NB4 AML cells served as calibrator and statistical significance was calculated by the Wilcoxon-Mann-Whitney test.